

Proposal serology EQA SARS-CoV-2

Panel composition – pos. samples	• Serum only (no saliva) • 2-3 samples with medium / high titers from severely ill cases • 2-3 samples with medium / high titers from mild cases • All pos. samples should be confirmed PCR-positive and from otherwise healthy individuals (i.e. not immunocompromised) • All pos. samples should be tested in as many tests as possible by INMI and RIVM: IF, Wantai, ELISA (?), automated system (?), VNT, other tests (?) -> IgG, IgM and IgA -> samples will always contain all subtypes or at least IgG and IgM (?)
Panel composition – neg. samples	• 2 x negative control samples -> serum collected before 2019 • If available serum with high beta-coronavirus titer -> RIVM has to check if possible • EBV infection serum • CMV infection serum
Panel properties	• 12 ml needed / sample • 9-11 samples / panel • 2 options for composition: ◦ 50 panels à 200 ul / sample ◦ 66 panels à 150 ul / sample • All sera have to be tested in PCR for Hepatitis A, B, C, E (?), HIV, SARS-CoV-2 • transport and storage conditions depend on lyophilization
Budget	• (10)(2b) for panel production and shipment • (10)(2b) for administrative costs
Open questions	• Can samples be lyophilized in time? • Which laboratories can participate – ECDC selection based on country (?) • How to proceed with heat inactivation?